Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.

Cancer medicine - 1 Jun 2016

Paoluzzi Luca, Hanniford Douglas, Sokolova Elena, Osman Iman, Darvishian Farbod, Wang Jinhua, Bradner James E, Hernando Eva

Abstract excerpt

Despite major advances in the treatment of metastatic melanoma, treatment failure is still inevitable in most cases. Manipulation of key epigenetic regulators, including inhibition of Bromodomain and extra-terminal domain (BET) family members impairs cell proliferation in vitro and tumor growth in vivo in different cancers, including melanoma. Here, we investigated the effect of combining the BET inhibitor JQ1...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Azepines
Share to Drug Synergism
Share to Indoles

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Melanoma

Share to Sulfonamides

Share to Triazoles

Share to Vemurafenib

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 27169980
DOI: 10.1002/cam4.667
PMCID: PMC4867668

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BET and BRAF inhibitors act synergistically against BRAF-mutant melanoma.PMID 27169980Read ↗

Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanomaSemantic proximity Read ↗

Targeting of super-enhancers and mutant BRAF can suppress growth of BRAF-mutant colon cancer cells via repression of MAPK signaling pathway.Semantic proximity Read ↗

BRD4 Sustains Melanoma Proliferation and Represents a New Target for Epigenetic TherapySemantic proximity Read ↗

The BRD9/7 Inhibitor TP-472 Blocks Melanoma Tumor Growth by Suppressing ECM-Mediated Oncogenic Signaling and Inducing ApoptosisSemantic proximity Read ↗

BET bromodomain inhibitor HMBA synergizes with MEK inhibition in treatment of malignant gliomaSemantic proximity Read ↗

Inhibition of NF-κB–Dependent Signaling Enhances Sensitivity and Overcomes Resistance to BET Inhibition in Uveal MelanomaSemantic proximity Read ↗

BET inhibitor in combination with BCG vaccine enhances antitumor efficacy and orchestrates T cell reprogramming for melanomaSemantic proximity Read ↗

<i>BCL2A1</i> is a lineage-specific antiapoptotic melanoma oncogene that confers resistance to BRAF inhibitionSemantic proximity Read ↗

Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma.Semantic proximity Read ↗

Preclinical Anticancer Efficacy of BET Bromodomain Inhibitors Is Determined by the Apoptotic ResponseSemantic proximity Read ↗

Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth.Semantic proximity Read ↗

Inhibition of endothelin-B receptor signaling synergizes with MAPK pathway inhibitors in BRAF mutated melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.